Unichem Laboratories
Unichem Laboratories Limited, commonly referred to as Unichem, is a prominent player in the pharmaceutical industry, headquartered in India. Established in 1944, the company has made significant strides in developing and manufacturing a diverse range of pharmaceutical products, including formulations and active pharmaceutical ingredients (APIs). With a strong presence in both domestic and international markets, Unichem operates in key regions such as North America, Europe, and Asia. The company is renowned for its commitment to quality and innovation, offering unique products that cater to various therapeutic segments, including cardiology, psychiatry, and anti-infectives. Unichem's dedication to research and development has positioned it as a trusted name in the industry, achieving notable milestones such as successful product registrations and strategic partnerships. With a robust portfolio and a focus on sustainable growth, Unichem Laboratories continues to enhance its market position as a leader in the pharmaceutical sector.
DitchCarbon Score
How does Unichem Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Unichem Laboratories's score of 4 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Unichem Laboratories's reported carbon emissions
In 2023, Unichem Laboratories reported total carbon emissions of approximately 88,302,000 kg CO2e, comprising about 13,842,000 kg CO2e from Scope 1 and about 74,188,000 kg CO2e from Scope 2 emissions. This represents a reduction in Scope 1 emissions from 16,125,000 kg CO2e in 2022, indicating a commitment to lowering direct emissions. However, Scope 2 emissions increased from 66,760,000 kg CO2e in the previous year. Unichem Laboratories has not disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or any formal climate pledges. The absence of defined reduction strategies suggests a need for enhanced climate commitments in line with industry standards. As a pharmaceutical company headquartered in India, Unichem Laboratories operates within a sector that is increasingly focused on sustainability and carbon footprint reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 16,125,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 66,760,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Unichem Laboratories is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
